Immunogenetics Laboratory, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Departments of Dermatology and Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
J Mol Diagn. 2019 Sep;21(5):852-861. doi: 10.1016/j.jmoldx.2019.04.009. Epub 2019 Jun 4.
The technical limitations of current next-generation sequencing technologies, combined with an ever-increasing number of human leukocyte antigen (HLA) alleles, form the basis for the additional ambiguities encountered at an increasing rate in clinical practice. HLA-DPB1 characterization, particularly, generates a significant percentage of ambiguities (25.5%), posing a challenge for accurate and unambiguous HLA-DPB1 genotyping. Phasing of exonic heterozygous positions between exon 2 and all other downstream exons has been the major cause of ambiguities. In this study, the Oxford Nanopore MinION, a third-generation sequencing technology, was used to resolve the phasing. The accurate MiSeq sequencing data, combined with the long reads obtained from the MinION platform, allow for the resolution of the tested ambiguities.
当前下一代测序技术的技术限制,加上人类白细胞抗原(HLA)等位基因数量的不断增加,是临床实践中越来越多遇到的额外歧义的基础。特别是 HLA-DPB1 特征描述,会产生大量的歧义(25.5%),对 HLA-DPB1 基因分型的准确性和明确性构成挑战。外显子 2 和所有其他下游外显子之间的异质位置的相位是造成歧义的主要原因。在这项研究中,第三代测序技术 Oxford Nanopore MinION 被用于解决相位问题。准确的 MiSeq 测序数据,加上从 MinION 平台获得的长读段,使得所测试的歧义得以解决。